CytomX Therapeutics, Inc. (CTMX) is highlighted as the eighth best biotech stock under $20 to buy now. Piper Sandler raised its price target on CTMX to $10, citing positive Phase 1 data for varsetatug maseatecan in colorectal cancer. Barclays analyst also raised the price target to $8, anticipating an attractive risk-reward profile ahead of a colorectal cancer readout. CTMX develops Probody therapeutics for cancer treatment. Analysts are bullish on CTMX, but some believe AI stocks offer greater upside potential with less risk.

Read more at Yahoo Finance: Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX)